Deciphera Pharmaceuticals Inc is a United States-based company. The Company is a biopharmaceutical company focused on discovering, developing, and commercializing new medicines to improve the lives of people with cancer. Its switch-control kinase inhibitor platform and applies research and development in kinase biology. The Company design kinase inhibitors to target the switch pocket region of the kinase with the goal of developing potentially transformative medicines through patient-inspired approach.

Employees

355

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Market Closed - Nasdaq Other stock markets 06:00:00 11/06/24 am AEST			5-day change	1st Jan Change
25.59 ^USD	+0.08%		-.--%	-

17/06	Deciphera Pharmaceuticals, LLC Doses First Patient In Pivotal Phase 3 INTREPID Study Of Sapablursen In Polycythemia Vera	CI
26/03	Ono Pharmaceutical Co., Ltd. Submits Application for Approval of Ripretinib in Japan	CI

Market Cap	2.21B 1.94B 1.81B 1.66B 3.12B 213B 3.16B 21.46B 8.39B 105B 8.31B 8.13B 362B	P/E 2022	-6.92x	P/E 2023	-7.04x
Enterprise Value	1.89B 1.66B 1.54B 1.41B 2.66B 182B 2.7B 18.29B 7.15B 89.29B 7.08B 6.93B 309B	EV / Sales 2022	5,951,009x	EV / Sales 2023	5,909,487x
Free-Float	71.62%	Yield 2022 *	-	Yield 2023	-

17/06	Deciphera Pharmaceuticals, LLC Doses First Patient In Pivotal Phase 3 INTREPID Study Of Sapablursen In Polycythemia Vera	CI
26/03	Ono Pharmaceutical Co., Ltd. Submits Application for Approval of Ripretinib in Japan	CI
17/02	Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL	CI
07/12	Deciphera Pharmaceuticals Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemiaera at the 67th American Society of Hematology Annual Meeting	CI
28/07/25	Deciphera Pharmaceuticals, Llc Announces Positive Chmp Opinion Forromvimza?? (Vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor	CI
15/02/25	Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Approval of Deciphera's Romvimza?? for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor	CI
12/06/24	Ono Pharmaceutical Closes Deciphera Deal for About $2.4 Billion	DJ
11/06/24	Deciphera Pharmaceuticals, Inc. Announces Board and Committee Changes	CI
11/06/24	Deciphera Pharmaceuticals Acquired by Ono Pharmaceutical for $2.4 Billion	MT
11/06/24	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index	CI
11/06/24	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Global BMI Index	CI
11/06/24	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P TMI Index	CI
11/06/24	Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from S&P Biotechnology Select Industry Index	CI

30/04/24	Barclays Upgrades Deciphera Pharmaceuticals to Equalweight From Underweight, Price Target is $26	MT
30/04/24	Leerink Downgrades Deciphera Pharmaceuticals to Market Perform, Price Target at $25.60	MT
30/04/24	JMP Downgrades Deciphera Pharmaceuticals to Market Perform	MT
30/04/24	JonesTrading Downgrades Deciphera Pharmaceuticals to Hold From Buy, Adjusts Price Target to $25.60 From $16	MT
30/04/24	Jefferies Downgrades Deciphera Pharmaceuticals to Hold From Buy, Trims Price Target to $25.60 From $26	MT

Deciphera Pharmaceuticals, Inc. Stock

Stocks

DCPH

US24344T1016

Biotechnology & Medical Research

Valuation: Deciphera Pharmaceuticals, Inc.

Latest news : Deciphera Pharmaceuticals, Inc.

Analysts' recommendations: Deciphera Pharmaceuticals, Inc.

Press Releases: Deciphera Pharmaceuticals, Inc.

News in other languages: Deciphera Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Deciphera Pharmaceuticals, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

03/06/24	Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet	BU
02/05/24	DECIPHERA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Deciphera Pharmaceuticals, Inc. - DCPH	BU
29/04/24	Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion	BU
09/04/24	Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum	BU
27/02/24	Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences	BU

15/01/22	En los barrios más pobres de Cuba, jóvenes podrían enfrentar décadas de cárcel tras las protestas
30/11/21	Barbados renuncia a la reina de Inglaterra para convertirse en una república

Manager	Title	Age	Since
Ryota Udagawa CEO	Chief Executive Officer	-	01/11/2024
Rodrigo Ruiz Soto CTO	Chief Tech/Sci/R&D Officer	-	01/01/2017
Dashyant Dhanak CTO	Chief Tech/Sci/R&D Officer	63	05/09/2023

Director	Title	Age	Since
Toichi Takino BRD	Director/Board Member	57	11/06/2024
Masayuki Tanigawa BRD	Director/Board Member	-	11/06/2024

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/6/24	Dashyant Dhanak	Free	Chief Technology Officer	345,001	0.3990%
11/6/24	Susan Kelley	Issuer sale	Director	85,339	0.0987%
11/6/24	Edward Benz	Issuer sale	Director	102,914	0.1190%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DECIPHERA PHARMACEUTICALS, INC.	+0.08%	-.--%	-.--%	+92.12%	2.21B
ARGENX SE	+0.93%	+6.97%	+62.83%	+67.97%	57.28B
WUXI APPTEC CO., LTD.	-1.92%	+6.03%	+43.68%	+84.56%	54.99B
INSMED INCORPORATED	-0.46%	-1.29%	+3.28%	+422.58%	23.18B
BIONTECH SE	-2.97%	-2.35%	-22.03%	-16.54%	22.59B
WUXI BIOLOGICS (CAYMAN) INC.	-0.36%	+5.73%	+30.99%	-3.58%	20.46B
GENMAB A/S	-1.34%	+0.51%	+25.02%	-30.27%	17.56B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.44%	+5.67%	+32.54%	+544.11%	15.67B
PHARMAESSENTIA CORPORATION	-1.30%	-5.02%	+165.62%	+291.37%	14.46B
EXELIXIS, INC.	-0.50%	-0.98%	+23.62%	+178.38%	13.92B
Average	-0.93%	+1.15%	+36.56%	+163.07%	24.23B
Weighted average by Cap.	-0.86%	+2.08%	+40.80%	+135.29%

	2022	2023
Net sales	134.04 117.72 109.48 100.46 188.76 12.91K 191.67 1.3K 507.92 6.35K 503.17 492.33 21.94K	163.36 143.48 133.43 122.44 230.05 15.73K 233.6 1.58K 619.02 7.73K 613.24 600.02 26.74K
Net income	-179M -157M -146M -134M -252M -17.23B -256M -1.74B -678M -8.47B -672M -657M -29.29B	-195M -171M -159M -146M -275M -18.77B -279M -1.89B -739M -9.23B -732M -716M -31.91B
Net Debt	-310M -272M -253M -232M -436M -29.85B -443M -3.01B -1.17B -14.67B -1.16B -1.14B -50.73B	-327M -287M -267M -245M -461M -31.49B -468M -3.17B -1.24B -15.48B -1.23B -1.2B -53.53B

3 years	9.9	25.61
5 years	6.51	37.99
10 years	6.51	71.11